ADC Therapeutics SA
Change company Symbol lookup
Select an option...
ADCT ADC Therapeutics SA
WDAY Workday Inc
BNOX Bionomics Ltd
NRDY Nerdy Inc
KEY KeyCorp
AMPX Amprius Technologies Inc
TPC Tutor Perini Corp
LTRN Lantern Pharma Inc
JGGC Jaguar Global Growth Corporation I
WHG Westwood Holdings Group Inc
Go

Health Care : Biotechnology | Small Cap Value
Based in Switzerland
Company profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Closing Price
$0.83
Day's Change
-0.0497 (-5.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.885
Day's Low
0.7001
Volume
(Light)
Volume:
157,722

10-day average volume:
296,832
157,722

Company Profile

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
0.38x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2023
Current Month
5.1M
Previous Month
5.1M
Percent of Float
9.43%
Days to Cover
13.9281 Days

Share Information

ADCT is in a share class of common stock
Float
54.3M
Shares Outstanding
80.6M
Institutions Holding Shares
62
54.99%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Ron R. Squarer
  • Ameet MallikCEO
  • Michael ForerVice Chmn.
  • Christopher Martin
  • Jose CarmonaCFO

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.